The delivery of Sputnik-5 Covid-19 vaccines will start from January, the international price will be less than 10 dollars | Russia’s Sputnik-5 will be available for $ 10, delivery from January

New Delhi: Right now, the world is waiting the most, so it’s the Covid-19 vaccine. WHO chief Tedros Edholm Ghebreyesis also said the real hope of ending the epidemic now lies only through vaccination. Vaccine makers have also given considerable relief by claiming that their vaccine candidates are 90-95% effective. Now the next question on people’s minds is their access to the vaccine and the cost of the vaccine to come.

Russian Sputnik-5 price revealed
Great information has been revealed about the world’s first registered Sputnik-5 vaccine. The Russian Direct Investment Fund (RDIF) released a statement on Tuesday, saying that a dose of Sputnik 5 (price per dose of vaccine) will be less than $ 10 on the international market. A person will need 2 doses of the vaccine. In other words, people will have to spend around $ 20 for this vaccine. However, this vaccine will be given free to Russian citizens.

Read also: Strict government action, ban of 43 mobile applications

Explain that this vaccine was jointly developed by the Gamalia National Research Center for Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF).

Delivery will start from January
International delivery of the Sputnik-5 vaccine will begin from January 2021. It will first be made available to those with whom the manufacturers have partnered. Speaking of its effects or results, according to the second interim analysis of the clinical trial, this vaccine was shown to be 91.4% effective after 28 days of the first dose.

Significantly, Russia claimed to manufacture 3 vaccines. On August 11, 2020, Russian President Vladimir Putin announced that Russia has manufactured a corona vaccine and its name is Sputnik-5. After that, experts around the world were surprised. Some scientists have said its clinical trials are being ramped up because trials were conducted on very few participants compared to standard numbers.

After that, Russia announced in October the creation of EpiVacCorona. At the same time, the third vaccine is being manufactured at the Chumakov Center of the Russian Academy of Sciences.